|
000
| 01899cam 2200277za 4500 |
|---|
| 001 | 9.853982 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107154946 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 181029s2018 oncd|||#o f000 0 eng d |
|---|
| 020 | |a9780660258522 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-212/2018E-PDF |
|---|
| 245 | 00|aUpdated recommendations on the use of herpes zoster vaccines |h[electronic resource]. |
|---|
| 246 | 1 |iAt head of title:|aAdvisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) |
|---|
| 260 | |aOttawa : |bPublic Health Agency of Canada,|c2018. |
|---|
| 300 | |a177 p. : |bcol. charts. |
|---|
| 500 | |aIssued also in French under title: Recommandations à jour sur l’utilisation des vaccins contre le zona. |
|---|
| 504 | |aIncludes bibliographic references: p. 63-72. |
|---|
| 520 | |a"The need for this updated National Advisory Committee on Immunization (NACI) Advisory Committee Statement on the Use of Herpes Zoster (HZ) Vaccines was triggered by evidence on a newly authorized Recombinant subunit Zoster Vaccine (RZV) vaccine, Shingrix®, indicated for the prevention of HZ in individuals 50 years of age and older. The primary objective of this statement is to review current evidence and develop guidance on the use of Shingrix®, as well as to provide guidance on whether the previously authorized Live Zoster Vaccine (LZV), Zostavax®II, and/or the recently authorized RZV should be offered to Canadians ≥50 years of age and older"--Introd., p. 6. |
|---|
| 692 | 07|2gccst|aImmunization |
|---|
| 692 | 07|2gccst|aInfectious diseases |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |bInfectious Disease Prevention and Control Branch. |
|---|
| 775 | 08|tRecommandations à jour sur l’utilisation des vaccins contre le zona |w(CaOODSP)9.853984 |
|---|
| 856 | 40|qPDF|s2.32 MB|uhttps://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-212-2018-eng.pdf |
|---|